Dejan Juric

20.4k total citations · 8 hit papers
252 papers, 8.0k citations indexed

About

Dejan Juric is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Dejan Juric has authored 252 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 166 papers in Pulmonary and Respiratory Medicine, 159 papers in Oncology and 89 papers in Molecular Biology. Recurrent topics in Dejan Juric's work include Advanced Breast Cancer Therapies (150 papers), Cancer Treatment and Pharmacology (83 papers) and HER2/EGFR in Cancer Research (66 papers). Dejan Juric is often cited by papers focused on Advanced Breast Cancer Therapies (150 papers), Cancer Treatment and Pharmacology (83 papers) and HER2/EGFR in Cancer Research (66 papers). Dejan Juric collaborates with scholars based in United States, Spain and France. Dejan Juric's co-authors include Hope S. Rugo, Ingrid A. Mayer, Sibylle Loibl, Mario Campone, Fabrice André, Pierfranco Conté, Hiroji Iwata, Toshinari Yamashita, David Mills and Eva Ciruelos and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Dejan Juric

243 papers receiving 7.9k citations

Hit Papers

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Po... 2014 2026 2018 2022 2019 2020 2014 2021 2018 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
    2019 1.6k citations Fabrice André, Eva Ciruelos et al. New England Journal of Medicine profile →
  2. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
    2020 371 citations Fabrice André, Dejan Juric et al. Annals of Oncology profile →
  3. CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
    2014 351 citations Dejan Juric, Alan Huang et al. profile →
  4. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
    2021 302 citations Noritaka Tanaka, W. Marston Linehan et al. Cancer Discovery profile →
  5. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →
  6. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
    2021 223 citations Hope S. Rugo, Eva Ciruelos et al. profile →
  7. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
    2024 68 citations Aditya Bardia, Ian E. Krop et al. Journal of Clinical Oncology profile →
  8. Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
    2025 16 citations Komal Jhaveri, Seock‐Ah Im et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dejan Juric United States 38 4.0k 3.8k 3.4k 2.0k 1.3k 252 8.0k
Jordi Rodón United States 48 5.8k 1.5× 4.1k 1.1× 2.4k 0.7× 2.3k 1.2× 1.4k 1.1× 402 10.2k
Dora Dias‐Santagata United States 44 3.2k 0.8× 3.5k 0.9× 2.2k 0.6× 1.6k 0.8× 781 0.6× 112 7.8k
Stefan Fröhling Germany 51 5.6k 1.4× 2.2k 0.6× 1.3k 0.4× 1.9k 1.0× 2.0k 1.5× 210 11.2k
Bijoyesh Mookerjee United States 30 4.1k 1.0× 3.7k 1.0× 2.2k 0.7× 2.3k 1.2× 533 0.4× 85 7.4k
Chris Tran United States 20 4.4k 1.1× 1.7k 0.5× 4.0k 1.2× 1.9k 1.0× 995 0.8× 23 8.7k
Sabine C. Linn Netherlands 48 3.2k 0.8× 4.7k 1.3× 2.4k 0.7× 3.4k 1.7× 668 0.5× 231 9.1k
Binghe Xu China 41 3.2k 0.8× 6.1k 1.6× 2.8k 0.8× 3.0k 1.5× 449 0.3× 387 9.1k
Seiji Yano Japan 46 4.3k 1.1× 5.2k 1.4× 4.9k 1.5× 1.6k 0.8× 359 0.3× 253 9.6k
Barry S. Taylor United States 46 5.5k 1.4× 3.3k 0.9× 2.7k 0.8× 3.0k 1.5× 459 0.4× 118 9.9k
Shan Man Canada 45 4.1k 1.0× 3.7k 1.0× 1.2k 0.4× 2.8k 1.4× 612 0.5× 83 7.5k

Countries citing papers authored by Dejan Juric

Since Specialization
Citations

This map shows the geographic impact of Dejan Juric's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dejan Juric with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dejan Juric more than expected).

Fields of papers citing papers by Dejan Juric

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dejan Juric. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dejan Juric. The network helps show where Dejan Juric may publish in the future.

Co-authorship network of co-authors of Dejan Juric

This figure shows the co-authorship network connecting the top 25 collaborators of Dejan Juric. A scholar is included among the top collaborators of Dejan Juric based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dejan Juric. Dejan Juric is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Durbin, Sienna, Andrea Pelletier, Laura A. Petrillo, et al.. (2024). Change in financial toxicity during early-phase cancer clinical trial (EP-CT) participation.. Journal of Clinical Oncology. 42(16_suppl). 11119–11119. 1 indexed citations
4.
Pelletier, Andrea, Sienna Durbin, Laura A. Petrillo, et al.. (2024). Associations of symptom burden with patient-reported outcomes (PROs) and clinical outcomes among early-phase cancer clinical trial (EP-CT) participants.. Journal of Clinical Oncology. 42(16_suppl). 11101–11101.
5.
Hamilton, Erika, Timothy Pluard, Judy S. Wang, et al.. (2024). H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 1015–1015. 4 indexed citations
6.
7.
8.
Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2023). 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Annals of Oncology. 34. S467–S467. 1 indexed citations
9.
Vidula, Neelima, Andrzej Niemierko, Jochen K. Lennerz, et al.. (2021). Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3404–3413. 12 indexed citations
10.
Tanaka, Noritaka, W. Marston Linehan, Chendi Li, et al.. (2021). Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation. Cancer Discovery. 11(8). 1913–1922. 302 indexed citations breakdown →
11.
Dudek, Arkadiusz Z., Dejan Juric, Afshin Dowlati, et al.. (2021). 476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results. Regular and Young Investigator Award Abstracts. A505–A506. 10 indexed citations
12.
Schettini, Francesco, Fabiola Giudici, Mario Giuliano, et al.. (2020). Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. JNCI Journal of the National Cancer Institute. 112(11). 1089–1097. 62 indexed citations
13.
André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940. 1565 indexed citations breakdown →
14.
Drago, Joshua Z., Luigi Formisano, Dejan Juric, et al.. (2019). FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer. Clinical Cancer Research. 25(21). 6443–6451. 47 indexed citations
15.
Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →
16.
Juric, Dejan, Ian E. Krop, Ramesh K. Ramanathan, et al.. (2017). Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery. 7(7). 704–715. 120 indexed citations
17.
Juric, Dejan, Johann S. de Bono, Patricia LoRusso, et al.. (2017). A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 23(17). 5015–5023. 76 indexed citations
18.
Bredel, Markus, Claudia Bredel, Dejan Juric, et al.. (2005). Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas. Cancer Research. 65(19). 8679–8689. 249 indexed citations
19.
Chen, Kevin G., Yan C. Wang, Marci E. Schaner, et al.. (2005). Genetic and Epigenetic Modeling of the Origins of Multidrug-Resistant Cells in a Human Sarcoma Cell Line. Cancer Research. 65(20). 9388–9397. 41 indexed citations
20.
Bredel, Markus, Claudia Bredel, Dejan Juric, et al.. (2005). High-Resolution Genome-Wide Mapping of Genetic Alterations in Human Glial Brain Tumors. Cancer Research. 65(10). 4088–4096. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jordi Rodón Breakdown of academic impact, for papers by Dora Dias‐Santagata Breakdown of academic impact, for papers by Stefan Fröhling Breakdown of academic impact, for papers by Bijoyesh Mookerjee Breakdown of academic impact, for papers by Chris Tran Breakdown of academic impact, for papers by Sabine C. Linn Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Seiji Yano Breakdown of academic impact, for papers by Barry S. Taylor Breakdown of academic impact, for papers by Shan Man
Rankless by CCL
2026